3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Glioma
3
Glioblastoma
3
Astrocytoma
2
Whooping Cough
1
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumococcal Infections
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Measles
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Hepatitis B
1
HIV Infections
1
Gliosarcoma
1
Carcinoma
1
Advanced Cancer
1
Interventions
Rituximab
205
Cyclophosphamide
178
Peripheral Blood Stem Cell Transplantation
93
Etoposide
91
fludarabine phosphate
86
Filgrastim
81
Melphalan
62
Vincristine
60
Mycophenolic Acid
58
Busulfan
58
Whole-Body Irradiation
57
Cytarabine
51
Radiotherapy
49
Doxorubicin
49
Cyclosporine
49
Tacrolimus
48
Granulocyte Colony-Stimulating Factor
48
Prednisone
46
fludarabine
45
Bendamustine Hydrochloride
45
Methotrexate
44
Carmustine
36
Antilymphocyte Serum
34
Dexamethasone
32
Bortezomib
29
Gemcitabine
27
ibritumomab tiuxetan
25
Methylprednisolone
23
sargramostim
22
Stem Cell Transplantation
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Non-Hodgkin
×
Tetanus Toxoid
×
Clear all
NCT01611298
2020-04-21
TAR
Baylor College of Medicine
Phase NA
Completed
7 enrolled
8 charts